Strengths

BMY’s ROIC of 15.5% indicates acceptable capital efficiency, but it remains below best-in-class large-cap pharma peers with stronger patent-led returns.

The company’s diversified portfolio across oncology, immunology, and cardiovascular drugs supports resilience, yet peers with newer growth franchises have clearer long-term demand momentum.

Cash conversion cycle of 43.0 days is manageable for a branded-drug manufacturer, although peers with stronger working-capital discipline typically convert cash faster.

BMY’s scale and global commercialization footprint help defend market access, but larger diversified peers often pair similar reach with stronger pipeline depth.

Weaknesses

Net debt to EBITDA of 2.1x leaves BMY more levered than several large-cap pharma peers, constraining flexibility versus balance-sheet-stronger competitors.

Debt to equity of 1.9x signals a heavier capital structure, which can pressure strategic optionality relative to peers with lower leverage.

Current ratio of 1.53 and quick ratio of 1.38 indicate adequate liquidity, but they are not meaningfully superior to peers with stronger near-term coverage.

BMY’s mature revenue base and patent-expiry exposure create greater earnings volatility than peers with more diversified late-stage pipelines.

Opportunities

Pipeline execution can improve peer positioning if late-stage assets convert, because successful launches would offset erosion from older brands.

Business-development activity could strengthen growth visibility, as peers have used targeted acquisitions to replenish pipelines and extend exclusivity.

Operational simplification and portfolio pruning could lift returns, since peers with sharper therapeutic focus often achieve higher margin consistency.

Improved capital allocation toward high-return assets could narrow the gap with peers that sustain stronger ROIC through disciplined reinvestment.

Threats

Patent expirations and biosimilar competition threaten core revenue streams, and peers with fresher portfolios face less near-term erosion.

Pricing pressure from U.S. payers and global reimbursement systems can compress margins, especially for mature brands versus peers with newer launches.

Pipeline setbacks would weigh more heavily on BMY than on peers with broader late-stage diversification and stronger internal replacement rates.

Higher leverage increases sensitivity to earnings disappointments, leaving BMY less resilient than balance-sheet-stronger peers during periods of slower growth.

Overall Score

BMY’s structural position is supported by scale and improved capital efficiency, but higher leverage and patent-driven maturity leave it behind stronger peer franchises.